Denali Therapeutics Inc. (DNLI) Spending and interest coverage
- R&D / revenue · 12 months: Value 11118.76%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 2638.40%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 11118.76% | Research and development expense / revenue. Period ending 2026-06-30. $400.72M ÷ $3.60M × 100 ≈ 11118.76% |
| Stock-based compensation / revenue · 12 months | 2638.40% | Share-based compensation / revenue. Period ending 2026-06-30. $95.09M ÷ $3.60M × 100 ≈ 2638.40% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 400.72M USD | Research and Development Expense |
| Revenue | 3.60M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 95.09M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -542.70M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $400.72M | $3.60M | $95.09M | $-542.70M | (m) | 11118.76% | 2638.40% | (m) | (m) |
| 2026-03-31 | $406.40M | (m) | $97.56M | $-547.12M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $418.78M | $0.00 | $99.63M | $-555.34M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $420.66M | (m) | $100.76M | $-547.82M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $416.95M | (m) | $100.48M | $-533.58M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $405.65M | (m) | $100.20M | $-515.21M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $396.44M | $0.00 | $102.88M | $-487.34M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $404.46M | $0.00 | $103.79M | $-490.07M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $395.95M | $1.27M | $106.39M | $-480.68M | (m) | 31251.38% | 8396.84% | (m) | (m) |
| 2024-03-31 | $402.08M | $295.39M | $107.86M | $-193.60M | (m) | 136.12% | 36.51% | (m) | (m) |
| 2023-12-31 | $423.88M | $330.53M | $108.10M | $-196.70M | (m) | 128.24% | 32.71% | (m) | (m) |
| 2023-09-30 | $408.18M | $340.79M | $107.30M | $-169.47M | (m) | 119.78% | 31.49% | (m) | (m) |
| 2023-06-30 | $406.23M | $339.71M | $104.42M | $-163.16M | (m) | 119.58% | 30.74% | (m) | (m) |
| 2023-03-31 | $401.45M | $98.06M | $101.79M | $-395.06M | (m) | 409.37% | 103.79% | (m) | (m) |
| 2022-12-31 | $358.73M | $105.06M | $99.85M | $-340.74M | (m) | 341.44% | 95.03% | (m) | (m) |
| 2022-09-30 | $334.50M | $107.32M | $96.75M | $-312.52M | (m) | 311.68% | 90.15% | (m) | (m) |
| 2022-06-30 | $318.27M | $112.42M | $93.16M | $-290.63M | (m) | 283.11% | 82.87% | (m) | (m) |
| 2022-03-31 | $291.24M | $82.88M | $90.36M | $-291.03M | (m) | 351.42% | 109.04% | (m) | (m) |
| 2021-12-31 | $265.35M | $48.66M | $85.25M | $-295.75M | (m) | 545.35% | 175.20% | (m) | (m) |
| 2021-09-30 | $252.22M | $352.95M | $76.99M | $25.45M | (m) | 71.46% | 21.81% | (m) | (m) |
| 2021-06-30 | $234.37M | $357.06M | $69.25M | $50.92M | (m) | 65.64% | 19.39% | (m) | (m) |
| 2021-03-31 | $221.81M | $339.93M | $60.59M | $51.47M | (m) | 65.25% | 17.83% | (m) | (m) |
| 2020-12-31 | $212.62M | $335.56M | $50.35M | $62.72M | (m) | 63.36% | 15.01% | (m) | (m) |
| 2020-09-30 | $209.42M | $23.71M | $45.41M | $-239.12M | (m) | 883.19% | 191.51% | (m) | (m) |
| 2020-06-30 | $208.26M | $27.83M | $41.06M | $-229.16M | (m) | 748.29% | 147.52% | (m) | (m) |
| 2020-03-31 | $207.00M | $26.12M | $42.29M | $-230.64M | (m) | 792.51% | 161.91% | (m) | (m) |
| 2019-12-31 | $193.38M | $26.68M | $38.38M | $-213.18M | (m) | 724.87% | 143.86% | (m) | (m) |
| 2019-09-30 | $181.74M | $147.68M | $35.13M | $-80.70M | (m) | 123.06% | 23.79% | (m) | (m) |
| 2019-06-30 | $159.52M | $135.27M | $31.74M | $-68.51M | (m) | 117.92% | 23.47% | (m) | (m) |
| 2019-03-31 | $159.77M | $132.72M | $22.74M | $-63.13M | (m) | 120.38% | 17.13% | (m) | (m) |
| 2018-12-31 | $143.18M | $129.16M | $18.79M | $-46.37M | (m) | 110.86% | 14.55% | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $74.46M | $0.00 | $4.41M | $-90.14M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $75.70M | $0.00 | $2.95M | $-87.43M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |